To date, various classes of drugs have been tested as potential anti-IBS therapy, for instance 5-HT3 antagonists and bile acid-binding agents (for IBS-D), 5-HT4 agonists, and chloride channel activators (for IBS-C) (Manabe et al. 2010). This evidence concerns the gene HTR3A and irritable bowel syndrome.